CABALETTA BIO, INC. Debt Securities, Available-for-sale
CABALETTA BIO, INC. (CABA) had Debt Securities, Available-for-sale of $133.60 million as of 2025-12-31, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-08-13
- 2025-12-31: Debt Securities, Available-for-sale $133.60M.
- 2025-09-30: Debt Securities, Available-for-sale $159.93M.
- 2025-06-30: Debt Securities, Available-for-sale $194.68M.
- 2024-09-30: Debt Securities, Available-for-sale $183.01M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2025-12-31 | $133.60M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $159.93M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $194.68M 10-Q · filed 2025-08-07 |
| 2024-09-30 | $183.01M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $203.22M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $223.84M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $241.25M 10-K · filed 2025-03-31 |
| 2023-09-30 | $164.39M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $176.33M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 |
| 2022-12-31 | $106.55M 10-K · filed 2024-03-21 |
| 2022-09-30 | $85.89M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $96.81M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $109.21M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-16 |
| 2021-09-30 | $119.26M 10-Q · filed 2021-11-01 |
| 2021-06-30 | $102.81M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $102.03M 10-Q · filed 2021-05-03 |
| 2020-12-31 | $108.66M 10-K · filed 2022-03-17 |
| 2020-09-30 | $118.07M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $123.18M 10-Q · filed 2020-08-06 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |